Equities research analysts expect Monopar Therapeutics Inc. (NASDAQ:MNPR) to report earnings per share (EPS) of ($0.15) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Monopar Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.13). Monopar Therapeutics reported earnings per share of ($0.13) during the same quarter last year, which indicates a negative year over year growth rate of 15.4%. The company is expected to issue its next earnings report on Friday, March 26th.
On average, analysts expect that Monopar Therapeutics will report full year earnings of ($0.54) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.52). For the next financial year, analysts forecast that the firm will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.37) to ($1.04). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Monopar Therapeutics.
Separately, Roth Capital started coverage on shares of Monopar Therapeutics in a research report on Thursday, January 28th. They issued a “buy” rating and a $49.00 price objective for the company.
In other news, major shareholder Tactic Pharma Llc sold 125,000 shares of the firm’s stock in a transaction dated Thursday, February 11th. The shares were sold at an average price of $14.64, for a total transaction of $1,830,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 48.40% of the company’s stock.
An institutional investor recently raised its position in Monopar Therapeutics stock. BlackRock Inc. boosted its holdings in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 99.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,391 shares of the company’s stock after purchasing an additional 2,688 shares during the quarter. BlackRock Inc.’s holdings in Monopar Therapeutics were worth $33,000 at the end of the most recent reporting period. 0.66% of the stock is currently owned by institutional investors and hedge funds.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers.
Further Reading: What is included in the gross domestic product?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.